<figure><img src="https://assets.bwbx.io/images/users/iqjWHBFdfxIU/ixtqwWh8_Hc8/v4/-1x-1.jpg"><figcaption><div><p>Source: Bloomberg, 07:55</p></div><div></div></figcaption></figure><p>Dr. Seth Lederman, immunologist, founder and CEO of Tonix Pharmaceuticals discusses concerns over Omicron subvariants in South Africa and development of Tonix&apos;s diagnostic skin test for T-cell immunity. He spoke to Bloomberg&apos;s David Westin.</p>

Dr. Seth Lederman, immunologist, founder and CEO of Tonix Pharmaceuticals discusses concerns over Omicron subvariants in South Africa and development of Tonix's diagnostic skin test for T-cell immunity. He spoke to Bloomberg's David Westin.

Balance of Power: Omicron Subvariant Raises Concerns

Bloomberg Washington Correspondents Joe Mathieu and Kailey Leinz deliver insight and analysis on the latest headlines from the White House and Capitol Hill